35results about "Spray delivery" patented technology

Provided are compositions and drug delivery systems containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions as diagnostics, and other such uses.

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Disclosed are compositions for the oral or nasal cavity. The compositions comprise a biologically active agent, a matrix forming agent comprising beta-glucan, and a bulking agent. The compositions can also comprise additional excipients, such as antioxidants, preservatives, taste or flavor enhancers, pH adjusting agents, plasticizers, and sweeteners. Also disclosed are methods of manufacturing the compositions.

Aspects of the present disclosure include a composition of nafamostat or a pharmaceutically acceptable salt thereof that provides for controlled release of nafamostat or pharmaceutically acceptable salt thereof to a subject for an extended period of time. Compositions according to certain embodiments include a plurality of controlled release beads where each bead includes a core, an active agent layer having nafamostat or a pharmaceutically acceptable salt thereof and a controlled release layer having one or more polymers formulated in an amount sufficient to provide for controlled release of the nafamostat or pharmaceutically 10 acceptable salt thereof. Methods for administering (e.g., orally) the controlled release nafamostat compositions to a subject are also described.

The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.

To provide novel compositions, etc. [Solution] The composition contains l-menthol and at least one component (X) selected from at least one selected from dicarboxylic acid esters, diol esters, monocarboxylic acid esters, esters of polyols having 3 or more hydroxyl groups, esters of polycarboxylic acids having 3 or more carboxyl groups, polyol ethers, polyamines, and alcohols having 6 or more carbon atoms.

There is provided an inhalation device for delivering a deliverable agent in the form of an aerosol or vapor to a user. The device comprises a solid, porous carrier material having a defined porosity, and a deliverable agent located within the pores of the carrier material. The device is operable to heat the carrier material and vaporize the deliverable agent. Deliverable agents that may be delivered to the user include nicotine. Suitable materials for the porous carrier material include chemically bonded ceramic materials and geopolymeric materials.

To provide antibiotic combination therapies for treating an A. baumannii infection in a subject.SOLUTION: Provided are combination therapies comprising rifabutin and a second antibiotic (for example, colistin and cefiderocol). The combinations of antibiotics display synergy to a wide range of A. baumannii strains, the synergy greatly increasing the susceptibility of A. baumannii cells to rifabutin and colistin, with some strains displaying over a 500-fold increase in sensitivity to one of those antibiotics used in combination with the other compared to when that antibiotic is used by itself.SELECTED DRAWING: None

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

A method of treating or preventing a bacterial infection in the lung of a subject by administering an inhaled antibiotic, and at least 37.5mg / day of an inhaled chelating agent, each in one or more doses, wherein the or each dose of the chelating agent and / or antibiotic is administered over a period of no more than 8h.

The present invention provides compounds, methods, and pharmaceutical compositions for treating asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), and ulcerative colitis. [Solution] Compounds, methods, and pharmaceutical compositions are provided for reducing the amount of SPDEF RNA in cells or a subject, and in some cases, the amount of SPDEF protein in cells or a subject.

A new class of dimeric 2-aminoimidazole (2-AI) compounds that potentiate macrolide antibiotics against A. baumannii. A parent dimer lowers the MIC of clarithromycin (CLR) from 32 μg / mL to 1 μg / mL at a concentration of 7.5 μM (3.4 μg / mL), while a structure activity relationship (SAR) study on the dimeric 2-AI scaffold resulted in the identification of several compounds with increased activity. Substitution of fluorine on a central phenyl ring resulted in the most potent activity, with the lead compound, containing a fluorine ortho to each of the 2-AIs, that lowered the CLR MIC to 2 μg / mL against AB5075 at 1.5 μM (0.72 μg / mL), exceeding the activity of both the parent dimer and the lead aryl-2-AI. Furthermore, these dimeric 2-AI analogs exhibit favorably low mammalian cell toxicity.

Provided herein is an inhalation formulation comprising a benzalkonium chloride (BKC) preservative and treprostinil or a pharmaceutically acceptable salt thereof. Also provided herein is an inhalation formulation comprising treprostinil or a pharmaceutically acceptable salt thereof and iloprost or a pharmaceutically acceptable salt thereof. Also provided herein is an inhalation device comprising the inhalation formulation and therapeutic methods of use of the inhalation formulation.

Methods for treating, improving, and / or preventing endothelial dysfunction caused by SARS-CoV-2 in subjects where such treatment is necessary are described herein. Methods for treating and / or improving coronavirus infection are also described herein. Both methods include administering an effective amount of a peptide capable of inhibiting the phospholipase A2 (PLA2) activity of peroxiredoxin 6 (Prdx6) to a subject.

A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.

This application relates to dry powder compositions for intranasal delivery. Specifically, it relates to a pharmaceutical composition in dry powder form for intranasal application, the pharmaceutical composition comprising solid particles of at least one active agent and solid particles of a diluent, the pharmaceutical composition being substantially free of excipients other than the solid diluent, wherein the pharmaceutical composition has at least 90% of the at least one active agent having particles with an average particle size of 10-30 micrometers, and less than 10% of the at least one active agent having particles with an average particle size equal to or less than 5 micrometers. The diluent particles have an average particle size of 30-200 micrometers. This application also relates to an apparatus and an improved spray drying method for preparing the pharmaceutical compositions of the invention in dry powder form.

An inhalation pharmaceutical composition containing a lipid carrier containing a drug, its therapeutic use, and a method for producing the same.

The present disclosure relates to methods and compositions comprising cannabidiol (CBD) and a volatile anaesthetic, particularly isoflurane, useful for treating or preventing traumatic brain injury (TBI).

Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.

Provided herein are pharmaceutical compositions containing (a) at least one liposome includes at least one vesicle-forming phospholipid; and (b) treprostinil encapsulated within the liposome. The ratio of treprostinil to phospholipid is equal to or higher than 0.035 and provides a controlled release of treprostinil. Also provided is the use of the pharmaceutical compositions to treat respiratory diseases.

The present invention provides stable, non-degradable, edible, inhalable, soluble, and drinkable compositions containing highly bioavailable pharmaceutical-grade ultra-fine active pharmaceutical ingredients with 99% purity and 200% increased bioavailability, and methods for their manufacture.

Methods for treating pulmonary hypertension are provided, including dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof. Dry powder inhalable compositions containing imatinib, a pharmaceutically acceptable salt, or a derivative thereof, as well as methods for their preparation are also provided.

The present invention relates to compounds of general formula (I) that inhibit discoidin domain receptors (DDR inhibitors), processes for the preparation of such compounds, pharmaceutical compositions containing them and their therapeutic use. The compounds of the invention may, for example, be useful in the treatment of a number of disorders associated with the DDR mechanism. JPEG2024510849000140.jpg5188

Disclosed is a nintedanib esylate inhalation powder composed of micronized nintedanib esylate and lactose monohydrate. Further disclosed are a preparation method for the nintedanib esylate inhalation powder and use thereof in the preparation of a drug for treating pulmonary diseases such as pulmonary diseases with fibrosis or lung cancer.

Providing ammonia-oxidizing microorganisms for use and delivery to the digestive system. [Solution] Provided are ammonia-oxidizing microbial preparations for delivery to the digestive system, a kit containing the ammonia-oxidizing preparations for delivery to the digestive system, and a device for administering the ammonia-oxidizing preparations to the digestive system. A method for introducing ammonia-oxidizing microorganisms into the digestive system is provided. A method for treating disorders, including digestive disorders and inflammatory disorders, with the ammonia-oxidizing microbial preparations is provided. In some embodiments, the preparations may be food products. Food products may include foods, beverages, dietary supplements, functional foods, additives, or medical nutrition products.

The application discloses a new subpopulation of human umbilical cord mesenchymal stem cells, exosomes, preparations and applications thereof, and particularly relates to a new subpopulation of human umbilical cord mesenchymal stem cells or exosomes purified from supernatant generated by the new subpopulation of human umbilical cord mesenchymal stem cells, which can be used for preparing a preparation for treating pulmonary fibrosis by atomization. In particular, the application comprises: a new subpopulation of human umbilical cord mesenchymal stem cells or a stem cell preparation; supernatant generated by the new subpopulation of human umbilical cord mesenchymal stem cells or exosomes purified from the supernatant; a preparation of exosomes purified from the supernatant generated by the new subpopulation of human umbilical cord mesenchymal stem cells; and a preparation of exosomes obtained by culturing the new subpopulation of mesenchymal stem cells for treating pulmonary fibrosis by atomization. The application has great value for treating and prognosis of pulmonary fibrosis and related diseases.

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and / or preventing postoperative tumor recurrence and / or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and / or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH from about 4.0 to about 7.5.